Nurix Therapeutics, Inc. (NRIX)
25.10
-0.71
(-2.75%)
USD |
NASDAQ |
Sep 11, 16:00
25.01
-0.09
(-0.36%)
After-Hours: 07:51
Nurix Therapeutics Enterprise Value : 2.218B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 2.218B |
| September 10, 2026 | 2.291B |
| September 09, 2026 | 2.338B |
| September 08, 2026 | 2.324B |
| September 04, 2026 | 2.325B |
| September 03, 2026 | 2.240B |
| September 02, 2026 | 2.292B |
| September 01, 2026 | 2.315B |
| August 31, 2026 | 2.288B |
| August 28, 2026 | 2.333B |
| August 27, 2026 | 2.402B |
| August 26, 2026 | 2.384B |
| August 25, 2026 | 2.409B |
| August 24, 2026 | 2.339B |
| August 21, 2026 | 2.386B |
| August 20, 2026 | 2.420B |
| August 19, 2026 | 2.496B |
| August 18, 2026 | 2.407B |
| August 17, 2026 | 2.432B |
| August 14, 2026 | 2.420B |
| August 13, 2026 | 2.434B |
| August 12, 2026 | 2.376B |
| August 11, 2026 | 2.307B |
| August 10, 2026 | 2.298B |
| August 07, 2026 | 2.262B |
| Date | Value |
|---|---|
| August 06, 2026 | 2.230B |
| August 05, 2026 | 2.220B |
| August 04, 2026 | 2.175B |
| August 03, 2026 | 2.023B |
| July 31, 2026 | 2.022B |
| July 30, 2026 | 2.060B |
| July 29, 2026 | 2.062B |
| July 28, 2026 | 2.119B |
| July 27, 2026 | 2.044B |
| July 24, 2026 | 2.039B |
| July 23, 2026 | 2.076B |
| July 22, 2026 | 2.062B |
| July 21, 2026 | 2.050B |
| July 20, 2026 | 1.970B |
| July 17, 2026 | 2.012B |
| July 16, 2026 | 2.007B |
| July 15, 2026 | 2.088B |
| July 14, 2026 | 1.998B |
| July 13, 2026 | 1.970B |
| July 10, 2026 | 2.006B |
| July 09, 2026 | 2.175B |
| July 08, 2026 | 2.136B |
| July 07, 2026 | 2.145B |
| July 06, 2026 | 2.108B |
| July 02, 2026 | 2.100B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cue Biopharma, Inc. | 141.71M |
| Keros Therapeutics, Inc. | -22.20M |
| Monte Rosa Therapeutics, Inc. | 616.02M |
| ACADIA Pharmaceuticals, Inc. | 3.908B |
| Alnylam Pharmaceuticals, Inc. | 32.94B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -89.54M |
| Revenue (Quarterly) | 9.043M |
| Total Expenses (Quarterly) | 98.58M |
| EPS Diluted (Quarterly) | -0.806 |
| Gross Profit Margin (Quarterly) | 57.43% |
| Profit Margin (Quarterly) | -990.1% |
| Earnings Yield | -13.74% |
| Normalized Earnings Yield | -13.74 |